FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote

An FDA advisory committee voted 17-1 on Wednesday that BrainStorm Cell Therapeutics did not demonstrate substantial evidence of efficacy for NurOwn in mild to moderate amyotrophic lateral sclerosis.